Pliant Therapeutics (PLRX) Gains from Sales and Divestitures (2019 - 2020)
Pliant Therapeutics (PLRX) reported Gains from Sales and Divestitures of $163568.0 for Q4 2020, up 25.57% quarter-over-quarter from $130257.0 in Q3 2020.
Pliant Therapeutics (PLRX) Gains from Sales and Divestitures (2019 - 2020) Analysis & Trends
Pliant Therapeutics (PLRX) has 2 years of Gains from Sales and Divestitures data on file, last reported at $163568.0 in Q4 2020.
- Gains from Sales and Divestitures for Q4 2020 came in at $163568.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2020 was $163568.0 (changed N/A YoY), and the FY2020 annual result was $163568.0, changed N/A from the prior year.
- Gains from Sales and Divestitures grew to $163568.0 in Q4 2020 per PLRX's latest filing, from $130257.0 in the prior quarter.
- Over five years, Gains from Sales and Divestitures peaked at $335610.0 in Q3 2019 and troughed at $92199.0 in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - |
| 10 | Pliant Therapeutics | 74.16 Mn | 74.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 163,568.00 |
| Dec 31, 2020 | 163,568.00 |
| Sep 30, 2020 | 130,257.00 |
| Sep 30, 2020 | 130,257.00 |
| Jun 30, 2020 | 92,199.00 |
| Jun 30, 2020 | 92,199.00 |
| Sep 30, 2019 | 335,610.00 |
| Sep 30, 2019 | 335,610.00 |
| Jun 30, 2019 | 225,551.00 |
| Jun 30, 2019 | 225,551.00 |